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The secretase BACE1 is fundamentally involved in the development of cerebral amyloid pathology in Alzheimer’s disease (AD). It
has not been studied so far to what extent BACE1 activity in cerebrospinal ﬂuid (CSF) mirrors in vivo amyloid load in AD. We
explored associations between CSF BACE1 activity and ﬁbrillar amyloid pathology as measured by carbon-11-labelled Pittsburgh
Compound B positron emission tomography ([11C]PIB PET). [11C]PIB and CSF studies were performed in 31 patients with AD.
Voxel-based linear regression analysis revealed signiﬁcant associations between CSF BACE1 activity and [11C]PIB tracer uptake
in the bilateral parahippocampal region, the thalamus, and the pons. Our study provides evidence for a brain region-speciﬁc
correlation between CSF BACE1 activity and in-vivo ﬁbrillar amyloid pathology in AD. Associations were found in areas close to
the brain ventricles, which may have important implications for the use of BACE1 in CSF as a marker for AD pathology and for
antiamyloid treatment monitoring.
1.Introduction
The cerebrospinal ﬂuid (CSF) is in close contact with the
extracellular space of the central nervous system; therefore,
pathologicalchangessuchasthoseduetoneurodegeneration
are reﬂected in CSF and alterations of biomarkers can
yield important mechanistic and diagnostic information on
disease processes. In Alzheimer’s disease (AD), a growing
number of CSF biomarkers are studied, some of which
mirror important events in the pathogenic cascade. These
markers include several indicators of changes related to the
amyloid cascade such as amyloid β 42 (Aβ42), total tau
and phosphorylated tau [1]. The amyloid hypothesis of AD
argues a cerebral accumulation of amyloid as primary driver
of AD pathogenesis, including amyloid plaque deposition,
neuroﬁbrillary tangle formation, synapse loss, and neuronal
cell death [2]. The amyloid deposits of insoluble protein
material mainly contain high levels of the 40 and 42 amino
acid long Aβ, which is produced through the cleavage of
a membrane-bound amyloid precursor protein (APP) by
the β-a n dγ-secretases. The cleavage of APP by the main
cerebral β-secretase (β-site APP-cleaving enzyme 1, BACE1)
[3]occursattheN-terminusoftheAβ-domainandresultsin
secreted soluble APP β (sAPPβ) and a C-terminal fragment
(C99) [4], which subsequently undergoes cleavage by γ-
secretase producing Aβ. The crucial role of BACE1 in AD
pathogenesis is highlighted by its increased enzyme activity
and protein concentration in AD brains [5]. Several previous
studies have shown that BACE1 activity can readily be
detected in CSF with activity increases in mild cognitive
impairment (MCI) and clinically diagnosable AD [6–8].
The relevance of BACE1 in the amyloid cascade is also
underscoredbyitspositiveassociationwiththeCSFproducts
of APP cleavage, including Aβ40 and sAPPβ [9]. Therefore,2 The Scientiﬁc World Journal
the value of BACE1 as a clinical biomarker for AD pathology
and for anti-amyloid treatment eﬀects is currently under
debate. Further in-vivo studies are urgently needed in order
to explore the association between CSF BACE1 activity and
amyloidpathologyinAD;modernimagingtechniquesmight
play an important role in this regard since they are able
to provide information about clinically suspected cerebral
pathology and its spatial distribution.
Recently,thecarbon-11-labeledpositronemissiontomo-
graphy (PET) tracer Pittsburgh’s Compound B ([11C]PIB)
became available as an in-vivo imaging tool for cerebral
amyloid deposits. Although [11C]PIB binds to several types
of cerebral Aβ, including plaque, nonplaque, and vascular
deposits, it has only minimal aﬃnity to other protein
aggregates such as Lewy bodies or neuroﬁbrillary tangles
[10–13]. Studies on patients with AD have demonstrated
an increased tracer uptake, even in very mild clinical
stages. Also, a progression of uptake with advancing clinical
disease severity has been discussed [14, 15]; however, it
seems that the progression of tracer uptake reaches a
plateau when AD becomes clinically diagnosable [16]. The
reported correlations between [11C]PIB tracer uptake and
CSF markers related to amyloid pathology such as Aβ42
further underscore the relevance of [11C]PIB PET imaging
as an AD biomarker [17–22].
In the present study, we quantitatively analyzed CSF
BACE1 activity and [11C]PIB tracer uptake in 31 patients
with probable AD, whose clinical diagnosis was supported by
an AD typical metabolic pattern in their ﬂuorine-18-labeled
ﬂuorodeoxyglucose ([18F]FDG) PET scans. Our main aim
was to explore associations between [11C]PIB tracer uptake
and BACE1 activity in CSF in order to provide evidence in
support of BACE1 activity as an in-vivo biomarker for AD
pathology.
2. Methods
2.1. Study Participants. Thirty-one patients with probable
AD were recruited from the outpatient memory clinic of
the Department of Psychiatry and Psychotherapy at the
Technische Universit¨ at M¨ unchen. The clinical diagnosis
was established by consensus of two experienced clinicians
according to the NINCDS-ADRDA criteria. The clinical
assessment included patient and proxy interviews, cognitive
testing, physical examination, routine blood and CSF sam-
pling, structural MRI, and [18F ] F D Ga sw e l la s[ 11C]PIB
PET imaging of the brain. The psychometric workup
was based on the Consortium to Establish a Registry for
AD (CERAD) neuropsychological battery, which includes
the Mini-Mental-State Examination (MMSE). Patients with
mild to moderate dementia, who had a typical metabolic
patternforADon[18F]FDGPETscans[23] wereincluded in
order to increase diagnostic accuracy. Patients were excluded
from the study if they met criteria for other neurological or
psychiatricdisordersincludingParkinson’sdisease,dementia
with Lewy bodies, frontotemporal dementia, progressive
supranuclear palsy, corticobasal degeneration, normal pres-
sure hydrocephalus, depression, or alcohol dependence. All
consecutive patients meeting the above in- and exclusion
criteria were enrolled; [11C]PIB PET scans and BACE1
activityvalueswerenotusedfordiagnosticpurposes.Written
informed consent was obtained from all participants accord-
ingtothe1975’sHelsinkiDeclaration,andthestudyprotocol
was approved by the ethics committee of the Medical Faculty
at the Technische Universit¨ at M¨ unchen.
2.2.BloodandCSFAssays. SerumandEDTAplasmasamples
for each subject were obtained by venous puncture for diag-
nostic purposes and genotyping. DNA was extracted from
blood using standard procedures, and the apolipoprotein E
(APOE) genotype was determined using polymerase chain
reaction and restriction enzyme digestion according to an
established standard protocol [24]. Patients were categorized
aseitherAPOEε4allelecarriersornoncarriersforthepresent
study. CSF (5–8mL) was collected in sterile polypropylene
tubes, using atraumatic cannulas placed in the L3/L4 or
L4/L5 intervertebral space, and gently mixed. In the native
CSF, determination of routine chemical parameters was per-
formed. Subsequently, the CSF was centrifuged for 10min
at 4000g, and aliquots of the remaining CSF supernatants
were immediately frozen at −80◦C for later determination of
ADparameters.TauandAβ42concentrationsweremeasured
in duplicate using enzyme-linked immunosorbent assay
(Innotest Innogenetics, Zwijndrecht, Belgium) as described
previously in detail [25].
BACE1 activity was measured using a time-resolved ﬂu-
orescence activity assay based on SignalClimb technology
(TruePoint Perkin Elmer, Turku, Finland) according to
optimized manufacturer’s instructions [6]. The synthetic
TruePoint BACE1 substrate is a ten amino acid long peptide
withaﬂuorescenteuropium(EU)chelatecoupledtooneend
and a quencher of europium ﬂuorescence (QSY7) coupled
to the other end via lysine. The hydrolysis of the substrate’s
protein sequence CEVNLDAEFK by BACE1 results in a
ﬂuorescence signal proportional to the activity of BACE1.
Theﬂuorescencesignalwasmeasuredat37◦Cinamicroplate
reader using time-resolved ﬂuorescence (FLUOstar Omega,
BMG Labtech, Oﬀenburg, Germany; excitation wavelength:
320nm, emission wavelength: 615nm) in black 96-well
plates (Perkin Elmer, Turku, Finland) at a ﬁnal volume of
27μL, including 10μLC S F ,2μLD M S O ,a n d1 5μLB A C E 1
substrate (0.80nmol/mL). The continuous measurement of
BACE1wasstartedimmediatelyafteraddingtheCSFsample;
BACE1 activity was deﬁned as the maximal activity within
theﬁrst30min.Eachsamplewasmeasuredatleastfourtimes
i no r d e rt ov e r i f yr e p r o d u c i b i l i t y .
2.3. Cerebral Imaging and Image Preprocessing. Structural
MRI, [18F]FDG PET, and [11C]PIB PET scans of the brain
were acquired according to published standard procedures
[14] within four weeks after the initial clinical assessment.
SPM8 software (Wellcome Functional Imaging Laboratory,
London, UK) based on Matlab v7 (The Mathworks Inc,
Natick, Mass USA) was used to preprocess and analyze the
[11C]PIB PET data. For spatial transformation of [11C]PIB
data, the individual standardized uptake value imagesThe Scientiﬁc World Journal 3
Table 1: Description of the study sample.
N 31
Male:female 19:12
Age, years∗ 65.8 (7.86)
MMSE∗ 23.9 (4.41)
CSF BACE1 activity, FU/μl∗ 7793 (2003)
APOE ε4+:ε4− 17:14
CSF tau (ng/L) 635.58 (310.39)
CSF Aβ42 (ng/L) 523.74 (116.79)
∗mean (SD), FU: ﬂuorescence units.
(40–70min p.i.) were coregistered to the corresponding
high-resolution MRI scans and then normalized to the Mon-
treal Neurological Institute space (MNI; bic.mni.mcgill.ca)
with the warping parameters of the individual’s MRI to
obtain images comparable between patients. In order to
adjust for interindividual diﬀerences in tracer uptake, a
relative measure of [11C]PIB was obtained by calculating a
cerebral to cerebellar vermis ratio as demonstrated previ-
ously [14]; brieﬂy, the uptake in all pixels of the subjects’
[11C]PIB scans was divided by the individual mean value in
the cerebellum. The individual normalized images were then
smoothed with a Gaussian kernel of 10 × 10 ×10mm.
2.4. Statistical Analysis. Patient characteristics were analyzed
in the Predictive Analytics Software package (PASW) v18
(TheSPSSInc.,Chicago,Ill,USA).Toexplorethecorrelation
between CSF BACE1 activity and [11C]PIB tracer uptake, a
voxel-based linear regression analysis was performed within
SPM8 with tracer uptake as the dependent variable and
CSF BACE1 activity as the independent variable, adjusting
for factors known to impact on [11C]PIB uptake and
amyloid pathology including APOE genotype [14, 26], age
[27], gender [28], and interval between PET scan and CSF
sampling [14]. A signiﬁcance threshold of P<0.001
uncorrected for multiple comparisons was applied as in
several previous studies using voxel-based multiple linear
regression approaches [26].
3. Results
PatientcharacteristicsareshowninTable1.Theaveragetime
interval between [11C]PIB PET scan and lumbar puncture
was 29 ± 41 days. Men and carriers of an APOE ε4
allele were slightly overrepresented in the sample. Visual
inspectionofthe[18F]FDGPETscansdemonstratedatypical
pattern for AD in all patients, that is, a bilateral aﬀection of
temporal and/or parietal and/or posterior cingulate cortex
[23]. The visual analysis of the [11C]PIB scans showed
an AD-typical tracer uptake as previously described in
all patients, including frontal and temporoparietal cortex,
precuneus, posterior cingulate gyrus, and striatum, and less
retention in sensorimotor, occipital, and cerebellar cortex
[26]. No patient showed a [11C]PIB-negative scan. The CSF
concentrations of tau and Aβ42 were in the expected ranges
f o rt h i st y p eo fs a m p l e[ 25].
The regression analysis with [11C]PIB tracer uptake as
the dependent variable and CSF BACE1 activity as the
independent variable, adjusted for covariates as described
above, revealed signiﬁcant positive associations in the bilat-
eral parahippocampal region, the right thalamus, and the
left pons (global maximum at MNI coordinates x/y/z
18/−24/−9, right parahippocampal gyrus, Brodmann area
35, P<0.001 uncorrected). No other brain region showed
a signiﬁcant correlation between BACE1 activity in CSF and
[11C]PIB tracer uptake (Table 2, Figures 1 and 2).
4. Discussion
APP cleavage by BACE1 is the rate-limiting step in the
production of Aβ and the activity of BACE1 in CSF can read-
ily be measured [29]; thus, CSF-based detection of BACE1
a c t i v i t ym i g h tb ev a l u a b l ei nt h ee a r l yd e t e c t i o n ,d i ﬀerential
diagnosis, and anti-amyloid treatment monitoring in AD.
Our results not only conﬁrm ﬁndings of previous studies
that suggest an association between BACE1 activity and in-
vivo amyloid pathology [5, 9] but also extend these earlier
investigations by presenting evidence for a region-speciﬁc
pattern of this relation, reporting a signiﬁcant positive
correlation between BACE1 activity in CSF and [11C]PIB
tracer uptake in the parahippocampal region, the thalamus,
and the pons.
Increased BACE1 expression, concentration, and activity
in and around senile plaques have been reported in several
studies in cognitively healthy elderly individuals and patients
with AD [5, 30, 31]. BACE1 activity increases, and correla-
tions with amyloid pathology were most consistently found
notonlyinAD-vulnerablebrainregionssuchasthetemporal
cortex, the hippocampal region, as well as the prefrontal
cortex [32] but also in some less vulnerable structures in
the diencephalon and brain stem including the thalamus and
the pons [33, 34]. Furthermore, a coexpression of BACE1
and APP, which is a prerequisite for Aβ production, in
the hippocampal region has been reported in APP/BACE1
transgenic mice [35–37]. The ﬁndings of these postmortem
and animal model studies are corroborated by our in-vivo
ﬁndings; however, associations between BACE1 activity in
lumbar CSF and amyloid load in [11C]PIB PET scans were
not found in some of the previously reported brain regions
including the prefrontal cortex [31].
In line with our recent ﬁnding that the correlation
between CSF Aβ42 and [11C ] P I Bt r a c e ru p t a k ei ss t r o n g e s t
in brain regions close to the ventricles [20], our present
results may indicate that BACE1 activity measured in lumbar
CSF primarily reﬂects amyloid pathology in structures
bordering the ventricular system. This observation can
possibly be explained by the fact that CSF is drained from
the ventricles into the spinal space before a small part
of it reaches cortical areas such as prefrontal cortex [38]
as well as the fact that proteins from ventricle remote
regions are drained via other ways including the perivascular
interstitial ﬂuid channels following the cortical arteries [39].
Therefore, BACE1 activity measured in lumbar CSF may
predominantly correspond to the enzymatic activity located4 The Scientiﬁc World Journal
Table 2: Peak correlations between [11C]PIB tracer uptake and CSF BACE1 activity.
Region xyz Z -score Cluster
Parahippocampal gyrus (r), BA 35 18 −24 −9 3.91 733
Parahippocampal gyrus (l), BA 28 −24 −24 −6 3.58 372
Parahippocampal gyrus (l), BA 35 −14 −13 −28 3.51 235
Thalamus (r) 2 −19 3 3.02 733
Pons (r) 8 −20 −38 3.12 495
Signiﬁcant brain clusters were labeled in Talairach daemon software (talairach.org/Daemon.html) after conversion of MNI (bic.mni.mcgill.ca) to Talairach’s
coordinates using the Matlab function mni2tal (http://imaging.mrc-cbu.cam.ac.uk/imaging/MniTalairach); brain regions are indicated by Talairach’s
coordinates; cluster: extent of contiguous voxels within the cluster; r: right, l: left; BA: Brodmann’s area.
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Figure 1: SPM8 maps of voxel-based correlations between [11C]PIB tracer uptake and CSF BACE1 activity. Anatomical localization as
projectedonaxialsectionsofanormalT1-weightedMRI,spatiallynormalizedintotheMNItemplateatthegiven z coordinatesinTalairach’s
space (P<0.01 uncorrected for display purposes; voxels outside of the brain and in the cerebellum are artifacts due to this threshold); color
bars represent Z-scores; images are displayed in neurological orientation (right side is right).
in speciﬁc brain structures. As an alternative explanation,
brain regional BACE1 activity diﬀerences might actually
exist in patients with clinically diagnosable AD, and the
plateau phase of [11C]PIB uptake increase in this disease
stage might further restrict the association to certain brain
areas.
Some limitations of our study have to be mentioned. The
patients were recruited from a specialized university center
and may, therefore, not truly represent the whole population
with AD. Furthermore, a modest number of patients were
included and replication in larger samples would be helpful.
An additional concern is the lack of pathologic conﬁrmation
of AD. However, the validity of present clinical diagnostic
criteria compared with autopsy diagnoses has been reported
to be very good in study cohorts recruited at specialized
centers[40];moreover,onlypatientswithatypicalmetabolic
pattern for AD on [18F]FDG PET scans were included.
Finally, although our cross-sectional study demonstrated a
correlation between BACE1 activity and in vivo amyloid
load, longitudinal studies are necessary to determine the
stability or variability of this association over time.
To conclude, our results point to an association between
BACE1 activity in lumbar CSF and in-vivo ﬁbrillar amyloid
pathologyinregionsadjacenttothebrainventricularsystem.
Thus, our data implicate that CSF BACE1 activity reﬂects
AD pathology in particular brain regions, whereas [11C]PIB
tracer uptake may map the entire cerebral amyloid load.
This observation suggests that BACE1 activity in CSF canThe Scientiﬁc World Journal 5
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Figure 2: Linear regression analysis of ﬁtted and adjusted [11C]PIB
uptake and CSF BACE1 activity at the localization of the most
signiﬁcant cluster (Talairach’s coordinates x/y/z 18/−24/−9, right
parahippocampal gyrus, Brodmann’s area 35), FU: ﬂuorescence
units.
only be considered a peripheral measure for AD pathology
in relation to certain brain regions. Our results support
the notion that CSF analysis may represent an important
tool for the detection of ongoing intracerebral pathology,
but complementation with imaging procedures may allow
the assessment of actual presence, quantity, and regional
distribution of pathology in the brain. It is also important
to note that the decision for or against CSF and imaging
biomarkers in clinical routine and treatment trials will also
depend on the willingness among clinicians to perform and
the willingness of patients to undergo lumbar puncture on
the one hand and access to cyclotrons and PET scanners
as well as ﬁnancial considerations on the other hand. Our
ﬁndings encourage further studies in order to explore the
value of BACE1 activity in CSF as a reliable, aﬀordable,
and easily accessible AD biomarker. However, our results
also narrow the possible applications of CSF BACE1 activity
due to its selective correlation with brain regional amyloid
pathology.
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